The vascular endothelial growth factor (VEGF) receptor subtype VEGFR-3 is only expressed on lymphatic endothelium in adults. However, VEGFR-3 is upregulated in the vasculature of tumours by Notch signalling. VEGFR-3 inhibition interferes with tumour angiogenesis and tumour growth, in particular in combination with inhibitors of the VEGFR-2, suggesting that it represents a novel anti-angiogenic target for cancer therapy.
- Tuomas Tammela
- Georgia Zarkada
- Kari Alitalo
